OncoMatch/Clinical Trials/NCT04812002
Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
Is NCT04812002 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PD-1 inhibitor， bevacizumab for gestational trophoblastic neoplasia.
Treatment: PD-1 inhibitor， bevacizumab — Gestational trophoblastic Neoplasia（GTN） is a kind of malignant tumor in women of childbearing age. It is easy to metastasized through the blood system in the early stage, so it is a relatively malignant tumor. The tumor is highly sensitive to chemotherapy, and low-risk patients have good prognosis, with survival rate and cure rate approaching 100%, but high-risk patients are prone to drug resistance, or relapse after remission. For relapsed, refractory, high-risk GTN, multiple remedies have been reported in the literature, but the remission rate is only 75-80%. For relapsed or refractory high-risk GTN, multiple remedies have been reported in the literature, but the remission rate is only 75-80%. Currently, targeted therapy and immunotherapy are widely used in various refractory solid tumors. For GTN, there are also a number of related studies. In this study, PD-1 inhibitors combined with bevacizumab were used to treat refractory high-risk GTN with relapse or drug resistance after receiving previous second-line or above multidrug combination therapy, to study the efficacy and safety of the treatment regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prior therapy
Must have received: multidrug chemotherapy
After treatment with at least two or more multidrug chemotherapy regimens
Cannot have received: anti-PD-1 therapy
Previously, he had received anti-PD-1, anti-PD-L1, bevacizumab and other drugs
Cannot have received: anti-PD-L1 therapy
Previously, he had received anti-PD-1, anti-PD-L1, bevacizumab and other drugs
Cannot have received: VEGFR inhibitor (bevacizumab)
Previously, he had received anti-PD-1, anti-PD-L1, bevacizumab and other drugs
Cannot have received: anticancer Chinese patent medicine
Within 2 weeks before the first administration, he had received anticancer Chinese patent medicine or immunomodulatory drugs
Cannot have received: immunomodulatory drugs
Within 2 weeks before the first administration, he had received anticancer Chinese patent medicine or immunomodulatory drugs
Lab requirements
Blood counts
anc≥1.5×109/l, pt ≥100×109/l, hb≥90g/l
Kidney function
bun and cr≤ normal value
Liver function
bil ≤ 1.5 times of the high limit of normal value, alt/alst ≤ 1.5 times of the high limit of normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify